Effects of Omega-3 Fish Oil Fat Emulsion on Rehabilitation and Immune Function After Radical Surgery Combined With Intraperitoneal Hyperthermic Infusion Chemotherapy in Patients With Locally Advanced Gastric Cancer

Launched by THE AFFILIATED HOSPITAL OF QINGDAO UNIVERSITY · Sep 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying whether omega-3 fish oil can help patients with advanced gastric cancer recover better after surgery and improve their immune system. The researchers want to see if taking omega-3 fish oil after surgery can lower inflammation, boost immune function, and even reduce hospital stays and costs for patients undergoing a specific type of chemotherapy combined with surgery.

To participate, individuals must be between 18 and 75 years old and have advanced gastric cancer that hasn't spread to other organs. They should also be in decent overall health, with no serious previous surgeries or other cancers. Participants will be asked to provide some background information and will receive omega-3 fish oil while their health indicators, like immune function and recovery time, are monitored. This study is currently looking for participants, and those who join will be contributing to important research that might help improve treatments for gastric cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The age is 18 to 75 years old.
• • For advanced gastric cancer, according to the TNM staging specified by the 8th edition AJCC, the clinical staging or EUS staging is above T2. There is no distant metastasis before operation, and the tumor does not directly invade the surrounding organs (liver, pancreas, spleen and transverse mesocolon, etc.).
• • There is no obvious contraindication to surgery.
• • The preoperative physical status score of Eastern American Cancer Cooperation (ECOG) was 0 or 1.
• • The preoperative ASA grade was grade Ⅰ-Ⅲ.
• • No previous history of gastric surgery, no history of other malignant tumors.
• • After explaining the nature and purpose of the study, agree to sign an informed consent form, give voluntary consent to participate in the study, and comply with the requirements of the study.
• Exclusion Criteria:
• • Radiotherapy or chemotherapy before operation.
• • Use of immunosuppressants such as hormones within 3 months before treatment.
• • Preoperative anemia (hemoglobin \< 90g/L) and severe hypoalbuminemia (albumin \< 30g/L).
• • With severe heart and lung and other important organ dysfunction.
• • More serious metabolic and immune diseases, such as hyperthyroidism, poor blood glucose control in diabetes, obesity, hyperlipidemia (triglyceride \> 3mmol/L, total bile solid \> 6.2mmol/L).
• • Severe infection before operation.
• • With complete intestinal obstruction, intestinal perforation and intestinal necrosis.
• • During the operation, it was found that radical operation could not be performed or combined organ resection was needed.
• • Operation time \> 6 hours, intraoperative bleeding \> 400ml